Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAd63 RH5 and MVA RH5 malaria vaccine study in Tanzanian adults, children, and infants
PACTR201710002722229Not yet recruiting
- Sponsor
- University of Oxford
- Start
- Jan 2018
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Trial of ChAd63 RH5 and MVA RH5 in malaria (5 arms), sponsored by University of Oxford. Primary endpoint: Adverse events. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
ChAd63 RH5MVA RH5
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR201710002722229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201710002722229.